SPOTLIGHT -
July 25th 2024
Insights from Takeda, Jazz, Nestlé Health Sciences, Humana, and other healthcare executives
July 15th 2024
The global president of endomechanical and energy for Johnson & Johnson MedTech discusses the need for multidisciplinary care when treating obesity.
July 12th 2024
The CEO of Revelation Pharma discusses how compounding pharmacies may help solve the ongoing issue with drug shortages.
June 25th 2024
David Minkin, President & GM at epocrates, offers his insights into the importance of trust, first-party data, and strategic partnerships in ensuring successful marketing campaigns.
June 5th 2024
Deployments are often built on the concept that growth comes from new prescribers, which may be limiting their success.
How GxP Leaders Can Assess and Approach a Company’s Quality Culture
Using the interview process to ensure high organizational standards.
Startup Launch Guide: Avoiding 10 Common Pain Points
With opportunity and risk lurking in equal measure, today’s key considerations for biopharma startups when building their leadership teams and product go-to-market strategies are outlined.
Making the Most of the Rising Biopharma M&As
Biopharma deal-making is on the rise again and now is the time for biopharma companies to embrace M&As to prepare for future growth.
Purposeful Partnerships for Post-COVID Era
Pharma should be the ‘glue’ that bonds healthcare organizations together to solve society’s most pressing challenges.
Digital Transformation: A Journey, Not Just a Destination
Amgen board member and serial CEO Fred Hassan talks about the three levers Fortune 500 C-suites should consider as they position their firms from pilots to enterprise-wide digital transformation.
SPACs: From Fad to Fixture: COVID Sparks Greater Use of IPO Alternative
The “blank-check” method has emerged as a worthwhile bet for biopharma companies looking to raise capital and go public, but will its attractiveness fade along with the pandemic?
Building Pharma and Lab Spaces in New Jersey 2021–Adapting to Changing Needs
NJ can regain leadership in pharma by offering modern lab spaces for biotech and other lab-based growth companies.
Uncover Potential Life Cycle Opportunities in Oncology Using Patient-Centric Outcomes
Focusing on prevention, diagnosis, treatment, and care monitoring during the patient journey in oncology to create value for stakeholders.
The Amazon Effect: A Data-Fueled Customer Experience
What the future emergence of Amazon Pharmacy and the company’s aim to own the health experience may mean for pharma manufacturers’ engagement strategies and role in Rx delivery.
Strategic Decision-Making in Early-Stage Drug Development and Lifecycle Management to Maximize a Drug’s Lifetime Value
Presenting a structured, decision-making approach for executive management to make sound strategic decisions for drug development and life cycle management.
Bridging the Generational Chasm in Oncology
How engaging with digital influencers holds the key for medical affairs.
Bringing Biosimilars to Market in Europe
If the life sciences sector can support healthcare professionals to gain confidence in substituting original treatments with new biosimilars, prices will reduce and patient outcomes will be enhanced.
How Just-in-Time Data Can Clear the Path to First Drug Launch
Implementing an efficient means of unifying disparate data and allowing teams to utilize this single source of truth data will allow them to track KPIs more effectively and get key insights when they need them.
Critical Connection: Patient Services and Product Launch
A look at best-practice approaches to aligning the strategy and design of hub service models with preparations for market entry of a new therapy.
Mastering the Transition From Academia to Industry
Tips for rounding out the rough edges in crossover.
Injecting Traditional Scientific Exchange with New Life
Female medical affairs leaders speak out with unique perspectives on how MSLs can provide greater value to opinion leaders.
Commercial Sustainability of Pharmaceutical Innovations for Pandemics
Assessing the landscape of the pharma industry’s readiness for future pandemics by looking at past pandemics, funding and revenue, and sustainability.
Best Practices for Balancing Medical Affairs Globalization with Local Requirements
Addressing the challenges faced by Global Medical Affairs teams and how they can find balance to create maximum value for their organizations.
Manage Risk Effectively to Improve the Value of Your Alliance
In this article, Eli Lilly & Co. examines risk management in the context of partnerships with other companies.
Planning Ahead for a Post COVID-19 Workforce and Workplace
Dr. George Westerman talks to Michael Wong about how smarter executives will successfully lead their workforces in a post COVID-19 business environment.
Drug Launch: Winning the Evidence Battle
Beyond necessity and nice-to-have, embracing real-world evidence as a true strategic differentiator.
New Standards for First-to-Launch Players
While COVID-19 has shifted some of the rules, research reveals that practice changes were already afoot for market newcomers.
(O)mega Opportunity: Vascepa
Uncovering fish oil derivative’s benefit for heart health.
Educational Mission: Oxbryta
New hope accompanies overdue recognition in sickle cell disease fight.
One Time for Lifetime: Zolgensma
The world’s most expensive drug put in context.
Unlocked Potential — ‘Keying’ in On New-Era Engagement
How adoption of the key account management (KAM) model can help drive pharma’s agility in reaching and influencing a more diverse set of healthcare customers and decision-makers.
Staying the Course in Product Launch
Amid pandemic, rely on the fundamentals.
Commercializing an Orphan Drug: Why “Just” Serving a High Unmet Medical Need Won’t Do the Job
Looking at four building blocks of success, Wolfram Lux and Simone Seiter investigate what it takes to win and be successful when commercializing an orphan drug
Don’t Waste A Crisis: How Paratek is Navigating the Business Implications of the COVID-19 Pandemic
A look at how pharmaceutical company, Paratek is navigating the launch of a new antibiotic during the COVID-19 pandemic.
How Pharma Reps and Managers Can Work to Overcome the In-Person HCP Barrier
While HCPs are turning away from in-person meetings with sales reps amidst the COVID-19 pandemic, there are still strategies for them to keep their pipelines full.